Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 26 Apr 2023
The dreaded hay fever signs, including itchy eyes, sneezing, and a stuffy nose, have arrived for many people with the arrival of spring. Up to 42% of people experience hay fever, making it a widespread condition. Immune system overreaction is the cause of it.
Read Full NewsA study of nearly 1 million veterans suggests that simpler lung cancer screening eligibility — based on smoking duration — would sharply reduce missed cancers and narrow disparities.
A large population study of young Black women aged 50 years or younger with invasive breast cancer highlights the importance of genetic testing in this population.
Eligible men with early prostate cancer can now be offered a high-precision radiotherapy technique on the NHS in England.
1.
Antitumor cell activity in glioblastoma is controlled by blocking the triggering receptor expressed on myeloid cells 2.
2.
FDA Approves Hemophilia B Second Gene Therapy.
3.
Pomalidomide Reduces Severe Epistaxis in Hereditary Bleeding Disease.
4.
Living near St. Louis-area Coldwater Creek during childhood linked with higher risk of cancer from radiation
5.
Highly Successful Treatment of Lynch Syndrome Patients with PD-1 Inhibitors for Colorectal Cancer.
1.
Adjuvant Atezolizumab in TNBC: What Recent Trials Reveal About Its Role
2.
Beyond the Human Eye: How AI Is Redefining Brain Cancer Diagnosis Through Advanced Imaging
3.
RDW-CV vs. MCV: Knowing the Difference Can Help You Better Understand Your Health
4.
Imaging in Peritoneal Neoplasms: Diagnostic Advances and Multimodal Treatment Strategies
5.
Everything You Need to Know About Leiomyomas: A Comprehensive Guide
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
International Lung Cancer Congress®
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
2.
Navigating the Complexities of Ph Negative ALL - Part V
3.
The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
4.
A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC
5.
Current Scenario of Cancer- The Incidence of Cancer in Men
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge